Innate Pharma Aktie News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Innate pharma aktie. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Innate Pharma Aktie Today - Breaking & Trending Today

Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update

07.05.2024 - Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Tuesday, May 14, 2024, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business . ....

Sonia Quaratino , Exchange Commission , French Financial Markets Authority , Company Annual Report On Form , Chief Executive Officer , Executive Vice President , Chief Medical Officer , Chief Operating Officer , Senior Vice President , Chief Financial Officer , Innate Pharma , Engager Therapeutics , Euronext Paris , Private Securities Litigation Reform Act , Risk Factors , Universal Registration Document , French Financial , Markets Authority , Annual Report , Innate Pharma Aktie , Nnate Pharma Spons Ads Aktie ,

Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi

19.12.2023 - Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and Sanofi (NASDAQ: SNY) announced today that Sanofi has exercised its option to license a natural killer (NK) cell engager program in solid tumors from Innate’s ANKET . Seite 1 ....

Valeria Fantin , Global Head Of Oncology Research At Sanofi , Global Head , Oncology Research , Engager Therapeutics , Innate Pharma Aktie , Nnate Pharma Spons Ads Aktie ,

Number of Shares and Voting Rights of Innate Pharma as of October 3, 2023

09.10.2023 - Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: . Seite 1 ....

Innate Pharma Aktie , Nnate Pharma Spons Ads Aktie ,

Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023

22.09.2023 - Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced an encore presentation of interim efficacy results from the TELLOMAK Phase 2 study in advanced Mycosis Fungoides (MF) according to . Seite 1 ....

Benefit Rate , Innate Pharma Aktie , Nnate Pharma Spons Ads Aktie ,